MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us





Back to products


Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer molecular libraries

Other drug agents

Drug intermediates

Bio-reagents and biochemicals


MedKoo product information:


 Elacridar Hydrochloride


Description of Elacridar: Elacridar, also known as GF120918A,  is a  P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.  In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog plasma. GF120918A did not demonstrate potent inhibition of several human cytochrome P450 enzymes evaluated in vitro, with IC(50) values well above concentrations anticipated to be achieved in vivo. Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in preclinical species and offer additional guidance on preclinical dose regimens likely to produce P-glycoprotein-mediated effects. (last updated: 6/9/2015).


MedKoo Cat#: 201190

Name: Elacridar HCl

CAS#: 143851-98-3 (elacridar hydrochloride); 143664-11-3 (free base)

Synonym: GF120918; GF-120918; GF 120918; GF-120918A; GF120918A; GF 120918A; GG 918; D03968. Elacridar hydrochloride.

IUPAC/Chemical name: 

N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-5-methoxy-9-oxo-9,10-dihydroacridine-4-carboxamide hydrochloride.

Smiles code: O=C(C(C=CC=C1C2=O)=C1NC3=C2C=CC=C3OC)NC4=CC=C(CCN5CC6=C(C=C(OC)C(OC)=C6)CC5)C=C4.[H]Cl

Chemical structure:

Theoretical analysis:


MedKoo Cat#: 201190
Name: Elacridar HCl
CAS#: 143851-98-3

Chemical Formula: C34H34ClN3O5

Elacridar (free base from)

Chemical Formula: C34H33N3O5

Exact Mass: 563.24202; Molecular Weight: 563.64

Elemental Analysis: C, 72.45; H, 5.90; N, 7.46; O, 14.19


Availability and price:

Elacridar HCl (99%) is in stock. Price reduced on 6/9/2015. The same day shipping out after order is received.  Delivery time: overnight (USA/Canada), 3-5 days (international). Shipping fee:  from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).

10 mg / $90.00

25 mg / $150.00

50 mg / $250.00

100 mg / $450.00

200 mg / $650.00

500 mg / $1,150.00  

1.0 g / $1,850.00  

2.0 g / $3,250.00  

5.0 g / ask price

Kilograms available at low price.


Also see other P-glycoprotein inhibitor: Elacridar; Tariquidar; Zosuquidar.



Technical data


Yellow solid powder


>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

View CoA, current batch, Lot#BBC50609

View CoA, previous batch, Lot#KB20120509

QC data:

View QC data, current batch, Lot#BBC50609

View QC data, previous batch, Lot#KN20120509.

Safety Data Sheet (MSDS):

View Material Safety Data Sheet (MSDS)

Shipping condition:

Shipped under ambient temperature as non-hazardous chemical.  This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage condition:

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).


Soluble in DMSO, not in water

Shelf life:

>2 years if stored properly

Drug formulation:

This drug may be formulated in DMSO

Stock solution storage:

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Note: The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.


Information about this agent

Phase I combined study of topotecan with Ellacridar: In part I, 20 patients were randomized to receive 100, 300, 500, 700, or 1,000 mg of elacridar on days 1 and 8 1 h before or simultaneously with 2.0 mg oral topotecan, which was also randomized. On day 15, all patients were treated with 1.5 mg/m(2) i.v. topotecan. In part II of the study, patients were treated daily with oral topotecan and with the lowest effective dose of elacridar following from part I. The maximum tolerated dose and dose-limiting toxicity were determined in cohorts of three patients. Blood samples were taken on days 1, 8, and 15 of part I and on day 1 of cycles 1 and 2 of part II. Complete apparent oral bioavailability of topotecan (102 +/- 7%) for all treatment arms with elacridar in both schedules was seen in part I. In the topotecan dose escalation part, two dose-limiting toxicities were seen at the 2.5 mg topotecan dose level.  CONCLUSION:  The recommended schedule is 2.0 mg oral topotecan plus 100 mg elacridar administered concomitantly daily times five every 21 days. (source: Clin Cancer Res. 2007 Jun 1;13(11):3276-85.).


1: Sane R, Agarwal S, Mittapalli RK, Elmquist W. Saturable active efflux by P-gp and Bcrp at the blood-brain barrier leads to non-linear distribution of elacridar to the central nervous system. J Pharmacol Exp Ther. 2013 Feb 8. [Epub ahead of print] PubMed PMID: 23397054.

2: Sane R, Mittapalli RK, Elmquist WF. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J Pharm Sci. 2013 Jan 18. doi: 10.1002/jps.23450. [Epub ahead of print] PubMed PMID: 23334925.

3: Bankstahl JP, Bankstahl M, Romermann K, Wanek T, Stanek J, Windhorst AD, Fedrowitz M, Erker T, Muller M, Loscher W, Langer O, Kuntner C. Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal PET and In-Vitro Study. Drug Metab Dispos. 2013 Jan 10. [Epub ahead of print] PubMed PMID: 23305710.

4: Kallem R, Kulkarni CP, Patel D, Thakur M, Sinz M, Singh SP, Mahammad SS, Mandlekar S. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier. Drug Metab Lett. 2012 Jun 1;6(2):134-44. PubMed PMID: 23061481.

5: Sarisozen C, Vural I, Levchenko T, Hincal AA, Torchilin VP. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. Drug Deliv. 2012 Nov;19(8):363-70. doi: 10.3109/10717544.2012.724473. Epub 2012 Oct 3. PubMed PMID: 23030458.

6: Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm. 2012 Nov 5;9(11):3236-45. doi: 10.1021/mp3003144. Epub 2012 Oct 18. PubMed PMID: 23020847.

7: Sane R, Agarwal S, Elmquist WF. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos. 2012 Aug;40(8):1612-9. doi: 10.1124/dmd.112.045930. Epub 2012 May 18. PubMed PMID: 22611067; PubMed Central PMCID: PMC3400790.

8: Wanek T, Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Sauberer M, Mairinger S, Strommer S, Wacheck V, Löscher W, Erker T, Müller M, Langer O. A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):149-59. doi: 10.1007/s00259-011-1941-7. Epub 2011 Oct 8. PubMed PMID: 21983837.

9: Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer. 2012 Jan 1;130(1):223-33. doi: 10.1002/ijc.26000. Epub 2011 Apr 7. PubMed PMID: 21351087.

10: Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Wanek T, Stundner G, Karch R, Brauner R, Meier M, Ding X, Müller M, Löscher W, Langer O. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging. 2010 May;37(5):942-53. doi: 10.1007/s00259-009-1332-5. Epub 2009 Dec 17. PubMed PMID: 20016890.


Contact MedKoo:

Tel: 919-636-5577
Fax: 919-980-4831





(Keyword; CAS#; MedKoo Cat#)




About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

© MedKoo Biosciences. All Rights Reserved